JP6242402B2 - 多汗症の治療 - Google Patents

多汗症の治療 Download PDF

Info

Publication number
JP6242402B2
JP6242402B2 JP2015551659A JP2015551659A JP6242402B2 JP 6242402 B2 JP6242402 B2 JP 6242402B2 JP 2015551659 A JP2015551659 A JP 2015551659A JP 2015551659 A JP2015551659 A JP 2015551659A JP 6242402 B2 JP6242402 B2 JP 6242402B2
Authority
JP
Japan
Prior art keywords
composition
itpr2
molecule
sirna
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015551659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505617A (ja
JP2016505617A5 (enExample
Inventor
ダール、ニクラス
Original Assignee
ハイドロス セラピューティクス インターナショナル アクチエボラグ
ハイドロス セラピューティクス インターナショナル アクチエボラグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハイドロス セラピューティクス インターナショナル アクチエボラグ, ハイドロス セラピューティクス インターナショナル アクチエボラグ filed Critical ハイドロス セラピューティクス インターナショナル アクチエボラグ
Publication of JP2016505617A publication Critical patent/JP2016505617A/ja
Publication of JP2016505617A5 publication Critical patent/JP2016505617A5/ja
Application granted granted Critical
Publication of JP6242402B2 publication Critical patent/JP6242402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015551659A 2013-01-03 2013-12-13 多汗症の治療 Active JP6242402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361748592P 2013-01-03 2013-01-03
US61/748,592 2013-01-03
PCT/SE2013/051508 WO2014107124A1 (en) 2013-01-03 2013-12-13 Treatment of hyperhidrosis

Publications (3)

Publication Number Publication Date
JP2016505617A JP2016505617A (ja) 2016-02-25
JP2016505617A5 JP2016505617A5 (enExample) 2016-09-15
JP6242402B2 true JP6242402B2 (ja) 2017-12-06

Family

ID=51062371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551659A Active JP6242402B2 (ja) 2013-01-03 2013-12-13 多汗症の治療

Country Status (6)

Country Link
US (2) US9809820B2 (enExample)
EP (1) EP2958572B1 (enExample)
JP (1) JP6242402B2 (enExample)
CN (1) CN105025903B (enExample)
CA (1) CA2896939C (enExample)
WO (1) WO2014107124A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958572B1 (en) * 2013-01-03 2019-10-23 Hidros Therapeutics International AB Treatment of hyperhidrosis
AU2016236521B2 (en) 2015-03-20 2019-03-07 Unilever Global Ip Limited Antiperspirant composition
CN110643598A (zh) * 2018-06-26 2020-01-03 煌鼎科技有限公司 促进皮肤凹疤愈合及毛孔收缩的酵母dna原料制法
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019055D0 (en) 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
KR20050057086A (ko) 2002-08-28 2005-06-16 홀리스-에덴 파마슈티칼즈, 인코포레이티드 치료적 처치 방법
EP1606406B2 (en) * 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
WO2007046102A2 (en) * 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
US8618160B2 (en) * 2007-10-18 2013-12-31 Rose U Topical glycopyrrolate formulations
WO2010065567A2 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
AU2010282273A1 (en) * 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
US20120207704A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
EP2958572B1 (en) * 2013-01-03 2019-10-23 Hidros Therapeutics International AB Treatment of hyperhidrosis

Also Published As

Publication number Publication date
US10633661B2 (en) 2020-04-28
CA2896939C (en) 2022-07-12
US20160122770A1 (en) 2016-05-05
US20180044682A1 (en) 2018-02-15
EP2958572B1 (en) 2019-10-23
CN105025903A (zh) 2015-11-04
EP2958572A1 (en) 2015-12-30
CA2896939A1 (en) 2014-07-10
US9809820B2 (en) 2017-11-07
JP2016505617A (ja) 2016-02-25
WO2014107124A1 (en) 2014-07-10
CN105025903B (zh) 2018-04-13
EP2958572A4 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
Wei et al. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway
US9376681B2 (en) miR-29 mimics and uses thereof
JP6140120B2 (ja) 挫瘡およびその他の状態を治療するためのビスファチン治療薬
Ding et al. Simvastatin alleviated diabetes mellitus‐induced erectile dysfunction in rats by enhancing AMPK pathway‐induced autophagy
JP6242402B2 (ja) 多汗症の治療
EP3750561A1 (en) Skin-permeating carrier containing nucleic acid complex and use thereof
JP6841871B2 (ja) 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物
Yang et al. Stimulation of epithelial sodium channels in endothelial cells by bone morphogenetic protein‐4 contributes to salt‐sensitive hypertension in rats
Song et al. Targeting a key pro-fibrotic factor S100A4 in cartilage to alleviate osteoarthritis progression and pain
CN113316459B (zh) 包含皮肤穿透核酸复合物作为有效成分的用于预防或治疗特应性皮炎的组合物
US20220249511A1 (en) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
JP2012502007A (ja) 強皮症の治療
US20230285336A1 (en) Composition for prevention and treatment of skin diseases caused by genetic mutation comprising ferulic acid and analogs thereof
Huang et al. ZC3H15 suppression ameliorates bone cancer pain through inhibiting neuronal oxidative stress and microglial inflammation
Newton et al. 1006 Reduction of type I interferon biomarkers by cGAS inhibition in scleroderma and GvHD skin
Ninkovic et al. 1003 Skin vaccination unravels novel intravascular CD8 memory T cell population which protects against influenza
Liu et al. 1005 MDI1228, a novel topical small molecule JAK inhibitor, alleviates autoimmune skin diseases by inhibiting dermal fibroblast-T cell interactions
Wu et al. 1002 A novel RXR agonist suppresses tumor formation accompanied by increased CD8+ T cells in a murine model of cutaneous T cell lymphoma (CTCL)
Ruel et al. 1007 Phloretin microneedle patches applied on human psoriatic reconstructed skin
Miao et al. 1004 Use of 2, 6-diaminopurine as a highly potent corrector of UGA nonsense mutations in recessive dystrophic epidermolysis bullosa
JP2023111535A (ja) セマフォリン３ａ発現促進剤
HK40052629A (en) Composition for preventing or treating atopic dermatitis comprising skin penetrating nucleic acid complex as an active ingredient
HK1191255A (en) Avian-based treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171107

R150 Certificate of patent or registration of utility model

Ref document number: 6242402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250